Patients with type 2 diabetes mellitus are exposed to an excessive heart failure risk
secondary to left ventricular hypertrophy and impaired diastolic filling, a condition not
addressed by currently available treatments. The abnormality results from obesity-induced
volume overload, increased blood pressure, and myocardial fat accumulation. By improving
metabolism, body weight, and blood pressure, Empagliflozin addresses the root causes of type
2 diabetes-associated myocardial disease. We will assess left ventricular mass, function, and
lipid content in patients with type 2 diabetes mellitus using cardiac magnetic resonance
imaging and spectroscopy as well as echocardiography before and after empagliflozin or
glimepiride treatment. We expect to observe improvements in left ventricular mass, function,
and fat content with empagliflozin. The results of the study will help to position
empagliflozin as an antidiabetic agent with the added value of protecting the heart.
Phase:
Phase 4
Details
Lead Sponsor:
Hannover Medical School
Collaborators:
Boehringer Ingelheim Hannover Clinical Trial Center GmbH